are winners!

Top News

 Vancouver, BC, Canada, May 18th, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vaccine) patients with pre-established cervical tumors.  The protection from cervical cancer can currently only be achieved with the use of Gardasil-9 or Cervarix, two ... [ more ]